Physician profile
Andrea Vu
NPI 1437131703
$2,956.47
in general payments reported to CMS, 2019-2025
32 companies · $933 in 2025
The $933 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $97.59 · 2021: $123 · 2022: $270 · 2023: $319 · 2024: $897 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $510.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $250.74 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $217.37 | 2019-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $207.68 | 2020-2025 | Rexulti |
| Lilly USA, LLC | $207.43 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $152.05 | 2023-2025 | |
| Amgen INC. | $135.81 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $123.71 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $72.07 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lundbeck LLC | $71.35 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $54.43 | 2019-2024 | Austedo Xr |
| Abbott Laboratories | $46.12 | 2021-2023 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $42.84 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.30 | 2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.55 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $27.12 | 2025 | Auvelity |
| Scilex Pharmaceuticals INC. | $26.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.06 | 2019 | |
| Astellas Pharma US INC | $24.70 | 2019 | |
| Radius Health, INC. | $23.63 | 2019 | |
| Alk-Abello, INC | $23.13 | 2025 | Grastek, Odactra, Ragwitek |
| Biogen, INC. | $22.23 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $22.21 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.34 | 2024 | Amvuttra |
| Avanir Pharmaceuticals, INC. | $18.79 | 2019 | |
| Allergan, INC. | $18.15 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.96 | 2024 | Trintellix |
| Amarin Pharma, INC. | $15.97 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.79 | 2019 | |
| Madrigal Pharmaceuticals | $14.89 | 2024 | Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.